(Chicago Popular) — – Welcome to the Chicago News. The subject of this news is Colon cancer, the surprising discovery of a new drug that is 100% effective
here are the details.
Colorectal cancer is one of the most common in industrialized countries. In Italy it represents the second malignancy for mortality after that of the lung
The attention of research, but also of the institutions, on colon cancer, one of the most dangerous, is growing more and more. Recent scientific studies give important hopes for the treatment of this disease that afflicts thousands of people every year.
Colorectal cancer is one of the most common in industrialized countries. In Italy it represents the second malignancy for mortality after that of the lung and for prevalence after that of the breast with thousands of cases every year. In Lazio it is estimated every year about 29 deaths per 100,000 men and about 19 deaths per 100,000 women. According to the cancer registry, almost 300,000 Italian citizens live with a previous diagnosis of colorectal cancer.
We said, however, that the institutions are also at the forefront. For example, what is happening in Lazio is commendable. For a few days, the Lazio pharmacies have lined up alongside the Region to screen for occult blood in faeces, often a precursor of colorectal cancer.
Screening as important as that of the colorectal which can make it possible to diagnose early on a disease that otherwise could turn into a very serious, painful and very often lethal pathology. Citizens of Lazio over 50 years old and familiar with colon cancer will receive an invitation from the Region to participate in the screening.
The citizen will receive free from the pharmacist the kit for the collection of feces, the explanations on the purposes and methods of the examination, then return the test tube to the pharmacy near the house. At that point the sample with the feces will be delivered to the ASL for analysis and the citizen will subsequently receive the report.
The new research
Screening is important. Just as research is important. And, on this point, important news arrives. The study was published in the New England Journal of Medicine. This drug appears to have very important effects on colon cancer patients.
It is a monoclonal antibody, which is called Dostarlimab, and which would be able to make the tumor lesion disappear. According to reports, it was given every 3 weeks for 6 months in patients with stage II or III rectal adenocarcinoma with maladjustment repair deficiency. And the results would be very encouraging.
In fact, the patients had a complete clinical response. The important thing is that with this drug there would be no need for other therapies (chemo, radio, surgery). There was also no serious side effect. The experiments were carried out on 12 patients. Obviously, further investigations will be needed to understand the actual validity of this cure, but certainly this is good news.